Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 3/2016

Open Access 01-03-2016 | Urosurgery (J Collins, Section Editor)

The Utility of Molecular Imaging in Prostate Cancer

Authors: Aaron Leiblich, Daniel Stevens, Prasanna Sooriakumaran

Published in: Current Urology Reports | Issue 3/2016

Login to get access

Abstract

Prostate cancer is the commonest solid-organ cancer diagnosed in males and represents an important source of morbidity and mortality worldwide. Imaging plays a crucial role in diagnosing prostate cancer and informs the ongoing management of the disease at all stages. Several novel molecular imaging technologies have been developed recently that have the potential to revolutionise disease diagnosis and the surveillance of patients living with prostate cancer. These innovations include hyperpolarised MRI, choline PET/CT and PSMA PET/CT. The major utility of choline and PSMA PET/CT currently lies in their sensitivity for detecting early recurrence after radical treatment for prostate cancer and identifying discrete lesions that may be amenable to salvage therapy. Molecular imaging is likely to play a future role in characterising genetic and biochemical signatures in individual tumours, which may be of particular significance as cancer therapies move into an era of precision medicine.
Literature
1.
2.
3.
DeSantis CE et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMed
4.
Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol. 2005;23(3):441–7.CrossRefPubMed
5.
6.
7.
8.
9.
Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer care. Mol Oncol. 2012;6(2):182–95.CrossRefPubMed
10.
11.
Scheenen TW et al. Multiparametric magnetic resonance imaging in prostate cancer management: current status and future perspectives. Invest Radiol. 2015;50(9):594–600.CrossRefPubMed
12.
Futterer JJ et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045–53.CrossRefPubMed
13.
Kwee SA et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173(1):252–5.CrossRefPubMed
14.
Scher B et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34(1):45–53.CrossRefPubMed
15.
Yamaguchi T et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32(7):742–8.CrossRefPubMed
16.•
Nelson SJ et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci Transl Med. 2013;5(198):198ra108. This important paper describes the first-in-man study evaluating the safety and utility of hyperpolarised pyruvate MR in imaging prostate cancer. The authors demonstrate the safety of this technique and also its efficacy in detecting biopsy proven prostate cancer.PubMedCentralCrossRefPubMed
17.
18.
Chen AP et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med. 2007;58(6):1099–106.CrossRefPubMed
19.
Lupo JM et al. Analysis of hyperpolarized dynamic 13C lactate imaging in a transgenic mouse model of prostate cancer. Magn Reson Imaging. 2010;28(2):153–62.PubMedCentralCrossRefPubMed
20.
Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51(5):1175–84.CrossRefPubMed
21.
Morigi JJ et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–90.CrossRefPubMed
22.
Souvatzoglou M et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17(11):3751–9.CrossRefPubMed
23.
Punnen S et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905–15.CrossRefPubMed
24.
Krause BJ et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):18–23.CrossRefPubMed
25.
Giovacchini G et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(6):1106–16.CrossRefPubMed
26.
Schillaci O et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39(4):589–96.CrossRefPubMed
27.
Heinisch M et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol. 2006;8(1):43–8.CrossRefPubMed
28.
Igerc I et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(5):976–83.CrossRefPubMed
29.
Vees H et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99(6):1415–20.CrossRefPubMed
30.••
Afshar-Oromieh A et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. This study evaluates the diagnostic value PSMA PET/CT as a tool for detecting recurrent prostate cancer in a large cohort of 319 patients. The authors demonstrate a high sensitivity for this technique as a tool for detecting recurrent disease. Of interest, recurrent lesions were even identified in men with PSA <0.2 ng/ml, demonstrating the utility of this approach in detecting very early recurrence.PubMedCentralCrossRefPubMed
31.
Budaus L, et al. Initial experience of Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2015.
32.
Dietlein M et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575–84.PubMedCentralCrossRefPubMed
33.
Sweat SD et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.CrossRefPubMed
34.
Mannweiler S et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72.CrossRefPubMed
35.
Rajasekaran SA et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4835–45.PubMedCentralCrossRefPubMed
36.
37.
Stenzl A. Salvage lymph node dissection in recurrent prostate cancer patients. Eur Urol. 2011;60(5):944–5.CrossRefPubMed
38.
39.
Schick U et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.CrossRefPubMed
40.
41.
Bayne CE, et al. Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives. Eur Urol, 2015.
42.
Sooriakumaran P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol, 2015.
43.
Bubendorf L et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.CrossRefPubMed
44.
Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
45.
Subramanian G, McAfee JG. A new complex of 99mTc for skeletal imaging. Radiology. 1971;99(1):192–6.CrossRefPubMed
46.
Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984;142(4):773–6.CrossRefPubMed
47.
Segall G et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51(11):1813–20.CrossRefPubMed
48.
Even-Sapir E et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.PubMed
49.
Hillner BE et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008;49(12):1928–35.CrossRefPubMed
50.
Hillner BE et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26(13):2155–61.CrossRefPubMed
51.
Morris MJ et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11(9):3210–6.PubMedCentralCrossRefPubMed
52.
Karantanos T et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67(3):470–9.CrossRefPubMed
53.
Liu A et al. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med. 1992;33(5):724–34.PubMed
54.
Larson SM et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45(3):366–73.PubMed
55.•
Vargas HA et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014;271(1):220–9. his study demonstrates that in men with castrate-resistant disease the number of bone lesions on FDHT PET/CT and the intensity of FDHT uptake is significantly associated with survival.PubMedCentralCrossRefPubMed
56.
Metadata
Title
The Utility of Molecular Imaging in Prostate Cancer
Authors
Aaron Leiblich
Daniel Stevens
Prasanna Sooriakumaran
Publication date
01-03-2016
Publisher
Springer US
Published in
Current Urology Reports / Issue 3/2016
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0573-z

Other articles of this Issue 3/2016

Current Urology Reports 3/2016 Go to the issue

Urosurgery (J Collins, Section Editor)

Novel Technologies in Urologic Surgery: a Rapidly Changing Scenario

Kidney Diseases (G Ciancio, Section Editor)

Rectourethral Fistula Management

Prostate Cancer (A Kibel, Section Editor)

Grading of Prostate Cancer: Past, Present, and Future

Female Urology (K Kobashi, Section Editor)

Pelvic Prolapse Repair in the Era of Mesh

Female Urology (K Kobashi, Section Editor)

Underactive Bladder

Prostate Cancer (A Kibel, Section Editor)

Prostate Cancer Imaging with Novel PET Tracers